用凝介导保存活瘤扩散剂,用于在腹腔转移中开发药物
Kenny Zhuoran Wu1, Rockie Haiyao Ding1, Zixuan Zhao2
1Department of Biomedical Engineering, National University of Singapore, 15 Kent Ridge Crescent, Singapore, 119276, Singapore.
Advanced materials (Deerfield Beach, Fla.)
|May 20, 2025
概括
新的氨酸水凝改善了患者衍生的瘤扩散物 (PDTE) 对于腹膜转移 (PM) 研究. 这种先进的模型更好地保留瘤特征,并预测药物疗效,帮助治疗开发.
科学领域:
- 生物医学工程 生物医学工程
- 在瘤学瘤学.
- 药物开发 药物开发
背景情况:
- 腹转移 (PM) 缺乏有效的临床治疗方法,需要改进临床前模型.
- 传统的患者衍生瘤扩展剂 (PDTE) 往往无法准确地代表原始瘤的生物学.
- 开发先进的模型对于加速药物发现和个人化医学在PM中至关重要.
研究的目的:
- 开发用于腹膜转移 (PM) 的氨酸 (HA) 水凝支持的PDTE,以更好地保留瘤特征.
- 调查水凝特性和酸盐在增强ex vivoPDTE模型中的作用.
- 建立一个更准确的平台来评估PM的治疗疗效.
主要方法:
- 工程化氨酸 (HA) 水凝以嵌入患者衍生的瘤扩散物 (PDTE) 来自腹转移 (PM).
- 研究了水凝参数 (刚性,降解,3D嵌入) 和HA对PDTE维护的影响.
- 纳入的患者入了ex vivo模型,以模拟瘤微环境.
主要成果:
- 通过保留组织学特征,组成和生物通路,HA水凝显著增强了PDTE维护.
- 水凝嵌入扰乱了肌肉蛋白II介导的组织收缩,改善了PDTE的活力.
- 炎的加入重新总结了瘤微环境,并揭示了炎依赖的药物疗效.
结论:
- 生物工程HA水凝支持的PDTE提供了一个优秀的平台来研究腹膜转移.
- 该模型准确地反映了瘤特征,并预测了药物反应,这对于治疗评估至关重要.
- 开发的模型有助于药物开发和针对腹膜转移的个性化治疗策略.
相关概念视频
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.